JOHNSON & JOHNSON (JNJ.DE) Stock Price, Forecast & Analysis
Europe - FRA:JNJ - US4781601046 - Common Stock
JNJ.DE Key Statistics, Chart & Performance
The current stock price of JNJ.DE is 161.94 EUR. In the past month the price decreased by -1.63%. In the past year, price increased by 11.42%.
JNJ.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SAN.PA | SANOFI | 11.42 | 211.47B | ||
| SNW.DE | SANOFI | 11.24 | 208.11B | ||
| MRK.DE | MERCK KGAA | 12.89 | 47.70B | ||
| UCB.BR | UCB SA | 34.92 | 43.61B | ||
| 1BAYN.MI | BAYER AG-REG | 5.28 | 26.00B | ||
| BAYN.DE | BAYER AG-REG | 5.29 | 26.03B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 25.56 | 10.53B | ||
| IPN.PA | IPSEN | 12.41 | 10.68B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 96.63 | 8.95B | ||
| VIRP.PA | VIRBAC SA | 19.93 | 2.90B | ||
| DMP.DE | DERMAPHARM HOLDING SE | 16.63 | 1.78B | ||
| MEDCL.PA | MEDINCELL SA | N/A | 981.08M |
Related stock screener links
About JNJ.DE
Company Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,100 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
Company Info
JOHNSON & JOHNSON
One Johnson & Johnson Plaza
New Brunswick NEW JERSEY US
Employees: 138100
Phone: 17325242455
JOHNSON & JOHNSON / JNJ.DE FAQ
Can you describe the business of JOHNSON & JOHNSON?
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,100 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
What is the current price of JNJ stock?
The current stock price of JNJ.DE is 161.94 EUR. The price increased by 0.07% in the last trading session.
Does JNJ stock pay dividends?
JOHNSON & JOHNSON (JNJ.DE) has a dividend yield of 2.78%. The yearly dividend amount is currently 4.25.
What is the ChartMill technical and fundamental rating of JNJ stock?
JNJ.DE has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the GICS sector and industry of JNJ stock?
JOHNSON & JOHNSON (JNJ.DE) operates in the Health Care sector and the Pharmaceuticals industry.
What is the Price/Earnings (PE) ratio of JOHNSON & JOHNSON (JNJ.DE)?
The PE ratio for JOHNSON & JOHNSON (JNJ.DE) is 18.03. This is based on the reported non-GAAP earnings per share of 8.98 and the current share price of 161.94 EUR.
What is JOHNSON & JOHNSON worth?
JOHNSON & JOHNSON (JNJ.DE) has a market capitalization of 390.01B EUR. This makes JNJ.DE a Mega Cap stock.
JNJ.DE Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to JNJ.DE. When comparing the yearly performance of all stocks, JNJ.DE is one of the better performing stocks in the market, outperforming 71.44% of all stocks.
JNJ.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to JNJ.DE. Both the profitability and the financial health of JNJ.DE get a neutral evaluation. Nothing too spectacular is happening here.
JNJ.DE Financial Highlights
Over the last trailing twelve months JNJ.DE reported a non-GAAP Earnings per Share(EPS) of 8.98. The EPS increased by 1.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 27.26% | ||
| ROA | 13.03% | ||
| ROE | 31.69% | ||
| Debt/Equity | 0.55 |
JNJ.DE Forecast & Estimates
31 analysts have analysed JNJ.DE and the average price target is 175.39 EUR. This implies a price increase of 8.31% is expected in the next year compared to the current price of 161.94.
For the next year, analysts expect an EPS growth of 9.86% and a revenue growth 5.62% for JNJ.DE